Surrozen Raises $50 Million in Series B Financing to Advance Regenerative Antibody Platforms and Liver Disease Candidates

    NEXT STORY
    Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
    PREV STORY
    Global Digital PCR Market to Reach $1.20 Bn by 2025 at 18.0% CAGR: AMR
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Versartis Announces Two Abstracts from Ongoing Pediatric Extension Study of Somavaratan Selected for Late-Breaker Presentations at the Endocrine Society’s 98th Annual Meeting

    MENLO PARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused ...

    author_avatar
    NASDAQ Market News

    Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results

    author_avatar
    NASDAQ Market News

    Faron Pharmaceuticals Oy: FDA grants Fast Track Designation to Faron for Traumakine®

    Faron Pharmaceuticals Ltd("Faron" or the "Company") FDA grants Fast Track Designation to Faron for ...

    author_avatar
    NASDAQ Market News